Key Highlights

  • NEXGEL (NASDAQ:NXGL) fell about 19% to USD 4.07 on Monday, October 26, 2026, two weeks after a 1-for-20 reverse split cut shares outstanding from about 9,747,663 to about 487,384.
  • iTonic Holdings (NASDAQ:ITOC) traded 7.14% higher at about USD 3.00, recovering part of a 13.31% fall on Friday, October 23, 2026, with about 7.32 million shares outstanding after a 16-for-1 consolidation.
  • Davion Healthcare (NASDAQ:DAVI) fell about 25% to USD 4.50 from a prior close near USD 6.00, within days of the expected start of Nasdaq trading on Thursday, October 22, 2026.
  • All three sell niche medical products through small share counts, and none has issued a release explaining Monday's move, so listing structure and financing risk frame the swings.

NEXGEL (NASDAQ:NXGL): a post-split decline with no new announcement

NEXGEL (NASDAQ:NXGL), based in Langhorne, Pennsylvania, makes hydrogels and sells the Biovance, Biovance 3L, Interfyl and SilverSeal wound care lines through its Bionx Surgical division. The shares fell about 19% to USD 4.07 in early trading on Monday, October 26, 2026, from a prior close near USD 5.03. The company has not issued a release explaining the move, and the decline is not a split artefact, because the 1-for-20 reverse split took effect two weeks earlier, at 12:01 a.m. ET on Monday, October 12, 2026. Shares outstanding fell from about 9,747,663 to about 487,384 before rounding, small enough to make the stock thinly traded.

A reverse split raises the quoted price without changing the value of the company, so it addresses a listing rule rather than the business. NEXGEL took the step to regain compliance with the exchange minimum bid price of USD 1.00, and the release states there is no assurance that it will succeed. After many such splits, shares fall back because holders sell into the higher price and because companies sometimes raise capital afterwards, which adds supply. The company reported second quarter 2026 revenue of about USD 3.69 million and a loss of about USD 2.87 million.

The principal risk is that the price falls back below USD 1.00 on an adjusted basis, or that the small share count produces wide swings. Any issuance would dilute holders heavily when so few shares exist. The company relies on a limited range of wound care and hydrogel products, its recent results show continuing losses, and investors should watch for a compliance confirmation from the exchange, the next quarterly results and any financing announcement.

iTonic Holdings (NASDAQ:ITOC): a rebound in a small float

iTonic Holdings Ltd (NASDAQ:ITOC), formerly Pheton Holdings Ltd, develops treatment planning software and devices for brachytherapy, a form of radiation cancer therapy, and an AI cloud platform for nuclear medicine planning, from Beijing. The shares traded 7.14% higher at about USD 3.00 in early trading on Monday, October 26, 2026. The move follows a fall of 13.31% to USD 2.80 at the close on Friday, October 23, 2026, so the shares regained roughly half of that decline, calculated from a prior level near USD 3.23. The company has not issued a release explaining the move.

After a 16-for-1 consolidation of Class A ordinary shares, effective on Tuesday, October 6, 2026, the company has about 7.32 million shares outstanding, which at USD 2.80 gives a market capitalisation near USD 20.5 million. Modest volumes can then move the price by double digits, so daily swings of 7% to 13% are consistent with the structure. The consolidation followed Nasdaq notices over the USD 1.00 minimum bid price, and the exchange granted an additional 180 days to regain compliance in April 2026.

The financial base is small: a trailing net loss of USD 8.92 million compares with revenue of USD 556,430, about 16 times revenue, calculated. A USD 200 million shelf registration permits future share sales and dilution, a securities class action over alleged nondisclosure has been filed, and Chinese regulatory and currency exposure add further risk. Formal confirmation of Nasdaq bid price compliance and any offering under the shelf are the items to watch.

Davion Healthcare (NASDAQ:DAVI): early price discovery for a new listing

Davion Healthcare (NASDAQ:DAVI) is a Dublin based company that develops home health monitoring devices, led by BreastCheck, an FDA registered at-home breast health screening test that runs in under 15 minutes. The shares fell about 25% to USD 4.50 in early trading on Monday, October 26, 2026, from a prior close near USD 6.00. The company has not issued a release explaining the move. Shares were expected to begin trading on the Nasdaq Global Market on Thursday, October 22, 2026, with Maxim Group acting as financial advisor, and new leadership took over at the start of trading.

A listing without a conventional offering leaves price discovery to the open market, so early sessions can swing widely. Direct commercialisation began in June 2026, and the company describes BreastCheck as not a replacement for mammography or clinical diagnosis. Much of the valuation rests on a plan to buy businesses with a five year senior secured bond of GBP 30 million, issued through Davion Healthcare Finance Ltd, a financing that carries interest costs and security over assets. A reported float of 25 million shares supplies the tradable base.

Volatility, funding and execution are the principal risks, and the first periodic filings after listing will show sales figures for BreastCheck. Leadership changed on the first day of trading, with Glenn Williams becoming chief executive officer and Jack Kaye moving to chairman, which adds integration risk, and home screening tests face regulatory and clinical scrutiny.

Where Things Stand

The answer is that share structure and listing status, not product news, drove the three moves. NEXGEL (NASDAQ:NXGL) trades on about 487,384 shares after a reverse split aimed at the USD 1.00 bid rule, iTonic Holdings (NASDAQ:ITOC) moved with about 7.32 million shares and a USD 200 million shelf behind it, and Davion Healthcare (NASDAQ:DAVI) fell 25% in its first week of trading with a GBP 30 million bond to fund acquisitions. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, any Nasdaq compliance notice at NEXGEL or iTonic, and the first filings and acquisitions at Davion. Micro cap shares are volatile and illiquid, and this is not investment advice.